Matthew Gline

Vorstandsvorsitzender bei ROIVANT SCIENCES LTD.

Vermögen: 500 Mio $ am 31.05.2026

41 Jahre

73 Beziehungen

Health Technology

Finance

Technology Services

Profil

Derzeit ist Matthew Gline Chief Executive Officer & Director bei Roivant Sciences Ltd. sowie Chief Executive Officer für Roivant Sciences GmbH und Chief Executive Officer für Roivant Sciences, Inc. (beides sind Tochtergesellschaften von Roivant Sciences Ltd.). Er ist außerdem Mitglied des Vorstands von Sumitovant Biopharma, Inc. In seiner früheren Laufbahn war Matthew Gline Chief Executive Officer & Director bei Montes Archimedes Acquisition Corp. Matthew Gline erwarb einen Bachelor-Abschluss am Harvard College.

Bekannte Unternehmensbeteiligungen

Unternehmen	Datum	Anzahl der Aktien	Bewertung	Datum der Bewertung
ROIVANT SCIENCES LTD. 2,32 %	30.06.2026	16 659 945 ( 2,32 % )	500 Mio $	31.05.2026

Aktive Positionen von Matthew Gline

Unternehmen	Position	Beginn
ROIVANT SCIENCES LTD.	Vorstandsvorsitzender	01.01.2021
ARBUTUS BIOPHARMA CORPORATION	Direktor/Vorstandsmitglied	24.02.2025
Roivant Sciences GmbH Roivant Sciences GmbH Pharmaceuticals: MajorHealth Technology Develops and markets biopharmaceutical products	Vorstandsvorsitzender	01.01.2021
Roivant Sciences, Inc. Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets drugs	Vorstandsvorsitzender	01.01.2021
Roivant Social Ventures, Inc. Roivant Social Ventures, Inc. Roivant Social Ventures, Inc. is a not-for-profit social impact organization dedicated to advancing health equity by applying private sector strategies to biopharma innovation and healthcare delivery. The private company is based in New York, NY. The company focuses on ensuring equitable access to medicines and medical care regardless of geography, wealth, or insurance status by investing in early-stage companies developing therapies for underserved patient populations, incubating healthcare-focused social entrepreneurs, and embedding drug development education in academic institutions through fellowships and internships to promote diversity in the biopharma industry and clinical trials. Roivant Social Ventures also partners with companies, institutes, and organizations to create systemic improvements in healthcare access and delivery, with key focus areas including gene therapy access, increasing diversity in clinical trials, and fostering diversity, equity, and inclusion opportunities for future biopharma leaders. Lindsay Androski has been the CEO of the company since 2016.	Direktor/Vorstandsmitglied	01.03.2016
Datavant, Inc. Datavant, Inc. Packaged SoftwareTechnology Services Operates as a health care software data platform company	Direktor/Vorstandsmitglied	-

Alle aktiven Positionen von Matthew Gline

Ehemalige bekannte Positionen von Matthew Gline

Unternehmen	Position	Ende
Goldman Sachs & Co. LLC Goldman Sachs & Co. LLC Investment Banks/BrokersFinance Provides brokerage services	Corporate Officer/Principal	01.01.2016
Fourthrev Ltd. Fourthrev Ltd. Packaged SoftwareTechnology Services Operates as an educational technology company that provides online learning program services	Gründer	01.03.2014
BARCLAYS PLC	Corporate Officer/Principal	01.01.2012
░░░░░░░ ░░░░░░░░ ░░░░	░░░░░░░░░░░░░░░░░░░░░	-
░░░░░░░░░░ ░░░░░░░░░░ ░░░░	░░░░░░░░░░░░░░░░░░░░░░░░░░	-

Sehen Sie sich die Erfahrung von Matthew Gline im Detail an

Ausbildung von Matthew Gline

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Sehen Sie sich die Erfahrung von Matthew Gline im Detail an

Beziehungen

Beziehungen ersten Grades

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Sehen Sie sich das persönliche Netzwerk an

Unternehmensverbindungen

Private Unternehmen	13
Arbutus Biopharma Corp. Arbutus Biopharma Corp. Pharmaceuticals: MajorHealth Technology Develops novel therapeutics which targets viral diseases	Health Technology
Roivant Sciences Ltd. Roivant Sciences Ltd. Pharmaceuticals: MajorHealth Technology Operates as a holding company through its subsidiaries develops restorative therapies for autoimmune diseases	Health Technology
Barclays PLC Barclays PLC Investment Banks/BrokersFinance Operates as a bank holding company whose subsidiaries engages in retail banking, credit cards, corporate and investment banking and wealth management services	Finance
Goldman Sachs & Co. LLC Goldman Sachs & Co. LLC Investment Banks/BrokersFinance Provides brokerage services	Finance
Harvard College Harvard College Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Roivant Sciences GmbH Roivant Sciences GmbH Pharmaceuticals: MajorHealth Technology Develops and markets biopharmaceutical products	Health Technology
Datavant, Inc. Datavant, Inc. Packaged SoftwareTechnology Services Operates as a health care software data platform company	Technology Services
Roivant Sciences, Inc. Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets drugs	Health Technology
Urovant Sciences Ltd. Urovant Sciences Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops and commercializes therapies for urologic conditions	Health Technology
Sumitovant Biopharma, Inc. Sumitovant Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets drugs	Health Technology
Montes Archimedes Acquisition Corp. Montes Archimedes Acquisition Corp. Financial ConglomeratesFinance Operates as a blank check company	Finance
Fourthrev Ltd. Fourthrev Ltd. Packaged SoftwareTechnology Services Operates as an educational technology company that provides online learning program services	Technology Services
Roivant Social Ventures, Inc. Roivant Social Ventures, Inc. Roivant Social Ventures, Inc. is a not-for-profit social impact organization dedicated to advancing health equity by applying private sector strategies to biopharma innovation and healthcare delivery. The private company is based in New York, NY. The company focuses on ensuring equitable access to medicines and medical care regardless of geography, wealth, or insurance status by investing in early-stage companies developing therapies for underserved patient populations, incubating healthcare-focused social entrepreneurs, and embedding drug development education in academic institutions through fellowships and internships to promote diversity in the biopharma industry and clinical trials. Roivant Social Ventures also partners with companies, institutes, and organizations to create systemic improvements in healthcare access and delivery, with key focus areas including gene therapy access, increasing diversity in clinical trials, and fostering diversity, equity, and inclusion opportunities for future biopharma leaders. Lindsay Androski has been the CEO of the company since 2016.